Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month Low - What's Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares reached a new 52-week low on Thursday . The company traded as low as $17.00 and last traded at $17.46, with a volume of 10727241 shares traded. The stock had previously closed at $18.98.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on SRPT shares. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 price objective (down from $113.00) on shares of Sarepta Therapeutics in a research note on Monday, June 16th. TD Cowen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target for the company. in a research report on Wednesday, June 18th. BMO Capital Markets downgraded Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $120.00 to $70.00 in a research note on Monday, June 16th. Mizuho decreased their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. Finally, Jefferies Financial Group dropped their target price on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a "buy" rating for the company in a report on Monday, June 16th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and an average target price of $60.88.

Sarepta Therapeutics Stock Performance

The firm has a market cap of $1.72 billion, a PE ratio of -6.49 and a beta of 0.61. The stock has a 50-day moving average price of $40.94 and a 200 day moving average price of $80.65. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same quarter last year, the firm earned $0.73 EPS. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. Research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC boosted its holdings in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after buying an additional 216 shares during the last quarter. Byrne Asset Management LLC purchased a new position in shares of Sarepta Therapeutics in the 1st quarter worth $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics in the first quarter valued at $31,000. Finally, Logan Capital Management Inc. acquired a new position in Sarepta Therapeutics in the fourth quarter valued at $61,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.